No Data
CareDx Is Maintained at Buy by Craig-Hallum
CareDx Is Maintained at Buy by Craig-Hallum
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Amgen (AMGN) and Orasure Technologies (OSUR)
Craig-Hallum: Maintaining the CaredX (CDNA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $22.00.
Craig-Hallum: Maintaining the CaredX (CDNA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $22.00.
Craig-Hallum Maintains Buy on CareDx, Raises Price Target to $22
Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $15 to $22.
Landmark Study Shows CareDx's HeartCare Outperforms Dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes With Fewer Biopsies
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive
HC Wainwright & Co. Reiterates Neutral on CareDx
HC Wainwright & Co. analyst Yi Chen reiterates CareDx with a Neutral.